Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Published:2012-02 Issue:2 Volume:61 Page:363-369
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Pond Gregory R.,Armstrong Andrew J.,Wood Brian A.,Brookes Melissa,Leopold Lance,Berry William R.,de Wit Ronald,Eisenberger Mario A.,Tannock Ian F.,Sonpavde Guru

Publisher

Elsevier BV

Subject

Urology

Reference17 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study;Berthold;J Clin Oncol,2008

3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

4. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group;Scher;J Clin Oncol,2008

5. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer;Sonpavde;J Clin Oncol,2011

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer;Journal of Modern Oncology;2021-11-19

2. Cancer Treatment–Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review;Indian Journal of Medical and Paediatric Oncology;2021-06

3. Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control;Chemotherapy;2021-01-22

4. Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer;The Scientific World Journal;2021-01-12

5. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands;Clinical Genitourinary Cancer;2019-10